Article
Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy
2025-10-29
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Durvalumab consolidation after concurrent chemoradiotherapy (cCRT) is the standard-of-care for unresectable stage III non–small cell lung cancer (NSCLC) without actionable driver mutations. However, pneumonitis remains a dose-limiting toxicity that often precludes or interrupts immunotherapy. Conventional predictors based on lung dosimetry alone exhibit limited individual-le...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ad901090-73ed-56b6-9316-e19052d688de
- DOI
- 10.1101/2025.10.27.25338565
